NASDAQ:ATAI Atai Life Sciences (ATAI) Stock Price, News & Analysis → Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad) Free ATAI Stock Alerts $1.32 -0.08 (-5.71%) (As of 06/11/2024 ET) Add Compare Share Share Today's Range$1.31▼$1.3950-Day Range$1.32▼$2.6052-Week Range$1.03▼$2.85Volume772,176 shsAverage Volume1.49 million shsMarket Capitalization$220.98 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Atai Life Sciences alerts: Email Address Atai Life Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside695.5% Upside$10.50 Price TargetShort InterestBearish5.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingSelling Shares$455,244 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.29 out of 5 starsMedical Sector480th out of 905 stocksPharmaceutical Preparations Industry228th out of 425 stocks 3.5 Analyst's Opinion Consensus RatingAtai Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtai Life Sciences has only been the subject of 3 research reports in the past 90 days.Read more about Atai Life Sciences' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.25% of the float of Atai Life Sciences has been sold short.Short Interest Ratio / Days to CoverAtai Life Sciences has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Atai Life Sciences has recently decreased by 3.17%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAtai Life Sciences does not currently pay a dividend.Dividend GrowthAtai Life Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATAI. Previous Next 3.0 News and Social Media Coverage News SentimentAtai Life Sciences has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Atai Life Sciences this week, compared to 2 articles on an average week.Search Interest16 people have searched for ATAI on MarketBeat in the last 30 days. This is an increase of 7% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Atai Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atai Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $455,244.00 in company stock.Percentage Held by Insiders31.20% of the stock of Atai Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.41% of the stock of Atai Life Sciences is held by institutions.Read more about Atai Life Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Atai Life Sciences are expected to remain at ($0.67) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atai Life Sciences is -5.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atai Life Sciences is -5.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtai Life Sciences has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Atai Life Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Atai Life Sciences Stock (NASDAQ:ATAI)Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Read More ATAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATAI Stock News HeadlinesJune 7, 2024 | proactiveinvestors.comatai Life Sciences poised for success with rigorous clinical trialsMay 31, 2024 | globenewswire.comatai Life Sciences to Participate in the Jefferies 2024 Global Healthcare ConferenceMay 29, 2024 | benzinga.comPsychedelic Investing For Beginners: Seize The Golden Moment!May 27, 2024 | seekingalpha.comATAI: Enormous Potential Upside But No Clarity YetMay 23, 2024 | finance.yahoo.comatai Life Sciences Strengthens Board with Appointment of Two New Independent DirectorsMay 23, 2024 | proactiveinvestors.comatai Life Sciences bolsters board with two new directorsMay 17, 2024 | markets.businessinsider.comBuy Recommendation for ATAI Life Sciences Amidst Cost-Optimization and Promising Clinical MilestonesMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for ATAI Life Sciences Amid Promising TRD Treatment Developments and Strategic Growth PotentialMay 16, 2024 | proactiveinvestors.comatai Life Sciences poised to create value as psychedelic therapies gain traction, analysts believeMay 15, 2024 | proactiveinvestors.comatai Life Sciences boss makes way for co-founder on better first quarterMay 15, 2024 | globenewswire.comatai Life Sciences Reports First Quarter 2024 Financial Results and Corporate UpdatesMay 2, 2024 | forbes.comHow AI Could Transform Drug Development And The Life SciencesMay 1, 2024 | finance.yahoo.comOpioid Withdrawal Syndrome Drug Market to Surge at a CAGR of 4.0% by 2034 | DelveInsightApril 30, 2024 | forbes.comAI Is Moving Biology From Science To Engineering, Advancing MedicineApril 24, 2024 | proactiveinvestors.comatai Life Sciences investee Beckey Psytech starts dosing patients in second part of treatment-resistant depression studyApril 24, 2024 | finance.yahoo.comatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant DepressionApril 24, 2024 | globenewswire.comatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant DepressionApril 18, 2024 | stockhouse.comatai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of PsychopharmacologyApril 18, 2024 | investing.comatai Life Sciences reports positive Phase 1 results for BPL-003April 17, 2024 | finance.yahoo.comatai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of PsychopharmacologyApril 17, 2024 | proactiveinvestors.comatai announces publication of Beckley Psytech's Phase 1 study for novel 5-MeO-DMT assetApril 17, 2024 | msn.comAtai Life Sciences N.V. (ATAI) Price Target Decreased by 15.35% to 10.90April 15, 2024 | proactiveinvestors.comatai Life Sciences CEO Florian Brand spotlights psychedelic therapy milestones and upcoming catalystsApril 6, 2024 | investing.comAtai Life Sciences executive sells $114k in company stockApril 4, 2024 | msn.comAre You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great ChoiceSee More Headlines Receive ATAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/17/2024Today6/11/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATAI CUSIPN/A CIK1420529 Webwww.atai.net.cn Phone49-89-2153-9035FaxN/AEmployees83Year FoundedN/APrice Target and Rating Average Stock Price Target$10.50 High Stock Price Target$15.00 Low Stock Price Target$6.00 Potential Upside/Downside+695.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,220,000.00 Net Margins-12,810.51% Pretax Margin-11,484.11% Return on Equity-43.21% Return on Assets-36.57% Debt Debt-to-Equity Ratio0.09 Current Ratio7.83 Quick Ratio7.83 Sales & Book Value Annual Sales$277,000.00 Price / Sales797.75 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book0.90Miscellaneous Outstanding Shares167,406,000Free Float115,175,000Market Cap$220.98 million OptionableOptionable Beta0.84 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Christian Angermayer (Age 46)Founder & Chairman of the Supervisory Board Comp: $70kMr. Florian Brand (Age 37)Co-Founder, MD & CEO Comp: $835.44kDr. Srinivas G. Rao M.D. (Age 55)Ph.D., Co-Founder & Chief Scientific Officer Comp: $834.15kMs. Anne Johnson (Age 55)Chief Financial Officer Dr. Michael Raven Ph.D.Senior Vice President of OperationsMr. Frank Stegert (Age 43)Vice President of Investment & Venture Management Mr. Ryan Barrett (Age 43)Senior VP, General Counsel & Corporate Secretary Dr. Glenn Short Ph.D.Senior Vice President of Early DevelopmentDr. Sahil V. Kirpekar M.D. (Age 38)Chief Business Officer Dr. Kevin Craig M.D.Senior Vice President of Clinical DevelopmentMore ExecutivesKey CompetitorsImmunomeNASDAQ:IMNMABIVAX Société AnonymeNASDAQ:ABVXOPKO HealthNASDAQ:OPKCentessa PharmaceuticalsNASDAQ:CNTAArcturus TherapeuticsNASDAQ:ARCTView All CompetitorsInsiders & InstitutionsFlorian BrandSold 151,303 sharesTotal: $290,501.76 ($1.92/share)China Universal Asset Management Co. Ltd.Bought 12,693 shares on 4/29/2024Ownership: 0.019%Quattro Financial Advisors LLCBought 70,976 shares on 4/18/2024Ownership: 0.043%CRA Financial Services LLCBought 12,903 shares on 4/17/2024Ownership: 0.008%Kingswood Wealth Advisors LLCBought 30,000 shares on 4/15/2024Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions ATAI Stock Analysis - Frequently Asked Questions Should I buy or sell Atai Life Sciences stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atai Life Sciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATAI shares. View ATAI analyst ratings or view top-rated stocks. What is Atai Life Sciences' stock price target for 2024? 3 analysts have issued 1-year price objectives for Atai Life Sciences' shares. Their ATAI share price targets range from $6.00 to $15.00. On average, they anticipate the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 695.5% from the stock's current price. View analysts price targets for ATAI or view top-rated stocks among Wall Street analysts. How have ATAI shares performed in 2024? Atai Life Sciences' stock was trading at $1.41 at the beginning of 2024. Since then, ATAI stock has decreased by 6.4% and is now trading at $1.32. View the best growth stocks for 2024 here. When is Atai Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ATAI earnings forecast. How were Atai Life Sciences' earnings last quarter? Atai Life Sciences (NASDAQ:ATAI) released its quarterly earnings results on Friday, May, 17th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.03. Atai Life Sciences had a negative net margin of 12,810.51% and a negative trailing twelve-month return on equity of 43.21%. What ETF holds Atai Life Sciences' stock? AdvisorShares Psychedelics ETF holds 200,207 shares of ATAI stock, representing 5.14% of its portfolio. What other stocks do shareholders of Atai Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atai Life Sciences investors own include Alphabet (GOOG), Baidu (BIDU), Costco Wholesale (COST), MannKind (MNKD), NVIDIA (NVDA), Schlumberger (SLB), Twitter (TWTR), Adobe (ADBE), Allergan (AGN) and Achaogen (AKAO). When did Atai Life Sciences IPO? Atai Life Sciences (ATAI) raised $200 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 14,300,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers. Who are Atai Life Sciences' major shareholders? Atai Life Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Quattro Financial Advisors LLC (0.04%), China Universal Asset Management Co. Ltd. (0.02%), Kingswood Wealth Advisors LLC (0.02%), CRA Financial Services LLC (0.01%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Anne Nagengast Johnson, Apeiron Investment Group Ltd, Christian Angermayer, Florian Brand, Gregory L Weaver and Srinivas Rao. View institutional ownership trends. How do I buy shares of Atai Life Sciences? Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATAI) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredBill Clinton Backing Biden Replacement???Bill Clinton is back. And he just met in Mexico with the one person I believe could REPLACE Joe Biden by Au...The Freeport Society | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atai Life Sciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Atai Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.